Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisRecruiting
NCT07321873Phase 2Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Arthritis, Psoriatic
United States, China, Czechia, Germany, Hungary +3 more
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompleted
NCT05304767Phase 3Updated Jul 31, 2026
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
United States, Bulgaria, Japan, Serbia
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)Recruiting
NCT05067283Phase 1Updated Jul 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Tumors
United States, Argentina, Australia, Canada, Chile +16 more
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisActive Not Recruiting
NCT05138133Phase 3Updated Jul 31, 2026
Sponsor: AstraZeneca
Lupus Nephritis
United States, Argentina, Belgium, Brazil, Bulgaria +19 more
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaRecruiting
NCT06894212Phase 3Updated Jul 31, 2026
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
United States, Japan
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyActive Not Recruiting
NCT05568095Phase 3Updated Jul 31, 2026
Sponsor: Arcus Biosciences, Inc.
Advanced Upper Gastrointestinal Tract Adenocarcinoma
United States, Argentina, Australia, Brazil, Canada +24 more
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisRecruiting
NCT05265273Phase 2, Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Myasthenia Gravis
United States, Japan, Netherlands, Poland
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
NCT07252232Phase 3Updated Jul 31, 2026
Sponsor: Revolution Medicines, Inc.
Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
United States, France, Germany, Italy, Japan +4 more
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCRecruiting
NCT04892173Phase 3Updated Jul 31, 2026
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Squamous Cell
United States, Austria, Belgium, Brazil, Bulgaria +22 more
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)Recruiting
NCT06146946NAUpdated Jul 31, 2026
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectal Cancer
China
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive Not Recruiting
NCT02446600Phase 3Updated Jul 31, 2026
Sponsor: National Cancer Institute (NCI)
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Transitional Cell Carcinoma · Fallopian Tube Undifferentiated Carcinoma · Ovarian Clear Cell Adenocarcinoma
United States, Canada, Japan, South Korea
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic AnemiaActive Not Recruiting
NCT04119050Phase 2, Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Warm Autoimmune Hemolytic Anemia
United States, Brazil, China, Czechia, Egypt +14 more
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisActive Not Recruiting
NCT07230860Phase 2Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Dermatitis, Atopic
United States, Argentina, Brazil, Canada, China +4 more
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 MutationsActive Not Recruiting
NCT04641442Phase 2Updated Jul 31, 2026
Sponsor: Novartis Pharmaceuticals
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
United States, Czechia, France, Italy, Japan +2 more
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisRecruiting
NCT06807424Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Arthritis, Psoriatic
United States, Argentina, Australia, Brazil, Bulgaria +19 more
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseActive Not Recruiting
NCT06544616Phase 2Updated Jul 31, 2026
Sponsor: Janssen Pharmaceutica N.V., Belgium
Alzheimer Disease
United States, Australia, Belgium, France, Germany +4 more
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's LymphomaActive Not Recruiting
NCT06470438Phase 1Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin · Refractory B-Cell NHL · Relapsed B-cell NHL
China, Italy, Japan, Poland, South Korea +2 more
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaRecruiting
NCT07266441Phase 2Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, China, Israel, Italy, Japan +3 more
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT07196748Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Colitis, Ulcerative
United States, Argentina, Australia, Belgium, Brazil +23 more
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive Not Recruiting
NCT06608927Phase 3Updated Jul 31, 2026
Sponsor: Arcus Biosciences, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
United States, Australia, Austria, Belgium, Canada +8 more
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseaseCompleted
NCT05987423Phase 3Updated Jul 31, 2026
Sponsor: Hoffmann-La Roche
Thyroid Eye Disease · TED
United States, Argentina, Australia, Austria, Germany +5 more
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisActive Not Recruiting
NCT06878404Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Arthritis, Psoriatic
United States, Argentina, Australia, Bulgaria, China +11 more
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerRecruiting
NCT07276399Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Squamous Cell Carcinoma of Head and Neck
United States, Australia, Austria, Belgium, Brazil +17 more
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)Recruiting
NCT06852222Phase 3Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
United States, Australia, Austria, Belgium, Brazil +20 more
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Recruiting
NCT07363590Phase 1Updated Jul 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus · Rheumatoid Arthritis
Australia, Belgium, China, Colombia, Georgia +5 more

Previous page Next page